Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody

European Journal of Cancer

Volumn 50, Issue 11, 2014, Pages 1891-1899

  Ormanns, Steffen ^a   Heinemann, Volker ^b,c   Raponi, Mitch ^d   Isaacson, Jeff ^d   Laubender, Rüdiger P ^a,c   Haas, Michael ^b   Kruger, Stephan ^b   Kleespies, Axel ^b   Mann, Elaina ^d   Bartosiewicz, Mike ^d   Kirchner, Thomas ^a,c   Boeck, Stefan ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Clovis Oncology Inc   (United States)

Author keywords

Gemcitabine; hENT1; Pancreatic cancer

Indexed keywords

CAPECITABINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; ERLOTINIB; GEMCITABINE; HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; RABBIT ANTISERUM; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ADVANCED PANCREATIC CANCER; AGED; ARTICLE; CANCER GROWTH; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TIME TO TREATMENT; TRANSLATIONAL RESEARCH;

GEMCITABINE; HENT1; PANCREATIC CANCER;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; QUINAZOLINES; RABBITS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84902258164     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.04.023     Document Type: Article

References (27)

1. A.S. Paulson, H.S. Tran Cao, M.A. Tempero, and A.M. Lowy Therapeutic advances in pancreatic cancer Gastroenterology 144 6 2013 1316 1326
2. H. Oettle, P. Neuhaus, and A. Hochhaus et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial JAMA 310 14 2013 1473 1481
3. J.P. Neoptolemos, D.D. Stocken, and C. Bassi et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 10 2010 1073 1081
4. A. Fukutomi, K. Uesaka, and N. Boku et al. JASPAC 01: randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer J Clin Oncol 31 suppl 15 2013 [ #4008]
5. V. Heinemann, M. Haas, and S. Boeck Systemic treatment of advanced pancreatic cancer Cancer Treat Rev 38 7 2012 843 853
6. T. Conroy, F. Desseigne, and M. Ychou et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 19 2011 1817 1825
7. D.D. Von Hoff, T. Ervin, and F.P. Arena et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 18 2013 1691 1703
8. J. Spratlin, R. Sangha, and D. Glubrecht et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma Clin Cancer Res 10 20 2004 6956 6961
9. C.W. Michalski, M. Erkan, and D. Sauliunaite et al. Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer Br J Cancer 99 5 2008 760 767
10. S. Pérez-Torras, J. García-Manteiga, and E. Mercadé et al. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer Biochem Pharmacol 76 3 2008 322 329
11. R. Maréchal, J.R. Mackey, and R. Lai et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma Clin Cancer Res 15 8 2009 2913 2919
12. J.J. Farrell, H. Elsaleh, and M. Garcia et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer Gastroenterology 136 1 2009 187 195
13. S. Morinaga, Y. Nakamura, and T. Watanabe et al. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy Ann Surg Oncol 19 suppl 3 2012 S558 564
14. R. Maréchal, J.B. Bachet, and J.R. Mackey et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma Gastroenterology 143 3 2012 664 674
15. N. Nakagawa, Y. Murakami, and K. Uemura et al. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection Surgery 153 4 2013 565 575
16. L.P. Jordheim, and C. Dumontet Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer? Biomark Med 7 4 2013 663 671
17. R. Kim, A. Tan, and K.K. Lai et al. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer Cancer 117 14 2011 3126 3134
18. N. Kawada, H. Uehara, and K. Katayama et al. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine J Hepatobiliary Pancreat Sci 19 6 2012 717 722
19. K. Eto, H. Kawakami, and M. Kuwatani et al. Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer Br J Cancer 108 7 2013 1488 1494
20. W. Greenhalf, P. Ghaneh, and J.P. Neoptolemos et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial J Natl Cancer Inst 106 1 2014 djt347 [Epub ahead of print]
21. E. Poplin, H. Wasan, and L. Rolfe et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity J Clin Oncol 31 35 2013 4453 4461
22. V. Heinemann, U. Vehling-Kaiser, and D. Waldschmidt et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104) Gut 62 5 2013 751 759
23. S. Boeck, A. Jung, and R.P. Laubender et al. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 Br J Cancer 108 2 2013 469 476
24. S. Boeck, A. Jung, and R.P. Laubender et al. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer J Gastroenterol 48 4 2013 544 548
25. M.A. Tempero, D. Klimstra, and J. Berlin et al. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer Clin Cancer Res 19 3 2013 538 540
26. S. Nakahira, S. Nakamori, and M. Tsujie et al. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts Anticancer Res 28 1A 2008 179 186
27. A.H. Ko, and M.A. Tempero Personalized medicine for pancreatic cancer: a step in the right direction Gastroenterology 136 1 2009 43 45